Todas las investigaciones
ReclutamientoFase I y Fase II (Integrada) - Primera administración a humanosIntervencionista

A seamless Phase I/II trial with an initial open-label dose escalation part and a subsequent randomised, double-blind, placebo-controlled expansion part to evaluate the safety, tolerability, and efficacy of a single dose of BI 3720931, an inhaled lentiviral vector gene therapy, in adult people with cystic fibrosis who are ineligible for CFTR modulators (LenticlairTM 1)

This research study, called LenticlairTM 1, is looking into a new inhaled gene therapy, BI 3720931, for adult patients with cystic fibrosis. It is for people who are not able to take existing CFTR modulator medicines. The study has two main parts. The first part will check for the best dose and how safe the treatment is. The second, larger part will compare the new treatment with a dummy treatment (placebo) to see if it helps improve lung function. Researchers will be carefully monitoring participants for any side effects and changes in their breathing over several weeks. The goal is to find out if this new gene therapy could be a safe and effective option for some people with cystic fibrosis.

De un vistazo

Estado
Reclutamiento
Fase
Fase I y Fase II (Integrada) - Primera administración a humanos
Patrocinador
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Objetivo de inscripción
12
Inicio
17 Jun 2024

¿De qué trata este estudio?

This study is looking at a new type of treatment for cystic fibrosis called BI 3720931. It's a gene therapy given through an inhaler, which means you breathe it in. This treatment aims to help people with cystic fibrosis by targeting the underlying genetic problem that causes the condition, rather than just treating the symptoms. This particular study is for adults with cystic fibrosis who are unable to use other specific cystic fibrosis medications known as CFTR modulators.

The study is called a 'seamless Phase I/II trial'. This means it combines two stages of research. In the first stage (Phase I), a small group of participants will receive increasing doses of the treatment. This helps researchers find the safest dose and see how well people tolerate it. In the second stage (Phase II), more participants will join. Some will receive the new gene therapy, and others will receive a dummy treatment (placebo) – neither the participants nor the doctors will know who is getting what until the end of the study. This helps to fairly assess if the new treatment is actually working.

The main goals are twofold: in Phase I, to monitor for any side effects or unwanted reactions to the new treatment for up to 24 weeks; and in Phase II, to see if the treatment improves lung function, specifically how much air you can breathe out in one second (FEV1pp), after 8 weeks. Researchers will also be looking at overall safety, other measures of lung function, and any serious side effects over a longer period.

Puntos clave

  • This study is testing a new inhaled gene therapy for cystic fibrosis.
  • It's for adults with CF who can't use certain other treatments.
  • The study will check for safety, tolerability, and effects on lung function.
  • It involves regular clinic visits, tests, and possible exposure to a placebo.
  • La participación es voluntaria, y puedes retirarte en cualquier momento.

¿Quién puede ser elegible?

This study is specifically looking for adult patients who have cystic fibrosis. You need to be at least 18 years old to take part, and there's no upper age limit currently stated.

Critically, this study is designed for adults with cystic fibrosis who are currently *not* able to use or take other specific cystic fibrosis medications called CFTR modulators. Your doctor will be able to tell you if this applies to you.

There may be other health requirements or conditions that would prevent you from joining, but these will be discussed in detail by the study team if you express interest.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tengo 18 años o más?
  2. Do I have a diagnosis of cystic fibrosis?
  3. Am I currently NOT taking CFTR modulator medicines?
  4. Am I unable to take CFTR modulator medicines for my cystic fibrosis?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you decide to take part in this study, you will have regular visits to the study clinic over several months. You will receive the study treatment, BI 3720931, through an inhaler, or a placebo (dummy treatment) if you are in the second part of the study. You'll likely undergo regular physical exams, blood tests, and lung function tests (like spirometry to measure your FEV1pp). The study also involves a special type of scan using a substance called Gadovist, which helps doctors see inside your body. You will be closely monitored for any side effects or changes in your health throughout the study. The exact number of visits, tests, and total duration will be explained by the study team, but based on the endpoints, your participation will involve follow-up for at least 24 weeks after receiving the treatment.

Riesgos y beneficios potenciales

Taking part in any research study involves potential benefits and risks. A potential benefit of joining this study is that you could receive a new gene therapy that might help your cystic fibrosis, especially if other treatments aren't suitable for you. However, there's no guarantee the treatment will work for you, or that it will be better than standard care. Potential risks include side effects from the investigational medicine (BI 3720931) or from the procedures involved, such as blood tests or scans. The study team will explain all known and possible risks in detail. Remember, participating is entirely voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Ubicaciones (4)

Algunas ubicaciones de los sitios son aproximadas. Estamos mejorando esto — por favor verifique con el equipo de prueba antes de viajar.
  • —
    No verificado
    Italia
  • —
    No verificado
    España
  • —
    No verificado
    Países Bajos
  • —
    No verificado
    Francia

Preguntas comunes

¿Qué es la terapia génica?

Gene therapy is a new type of treatment that aims to correct the genetic problem causing a disease, rather than just treating the symptoms.

What does FEV1pp mean?

FEV1pp is a measure of how much air you can forcefully breathe out of your lungs in one second. It's often used to check lung health in cystic fibrosis.

¿Qué es un placebo?

A placebo is a 'dummy' treatment that looks just like the real medicine but contains no active drug. It helps researchers fairly compare the new treatment.

Who cannot take part in this study?

Adults with cystic fibrosis who are currently using or are able to use CFTR modulator medicines are not eligible for this particular study.

Will I know if I'm getting the drug or placebo?

No, this is a 'double-blind' study, meaning neither you nor your study doctor will know whether you are receiving the active treatment or the placebo until the study ends.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "A seamless Phase I/II trial with an initial open-label dose …" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.